Our CD3xPDL1 BiTE uses the VH and VL regions of anti-CD3 mAb in combination with the VH and VL regions of the human anti-PD-L1 mAb 4A12 (80) to activate T cells and target them to PD-L1+ tumor cells. The gene discussed is CD274; the disease is neoplasm.